Background The role of host immunity in emergence of evasive SARS-CoV-2 Spike
mutations under therapeutic monoclonal antibody (mAb) pressure remains to be explored …

Neutralizing antibodies against the SARS-CoV-2 spike (S) protein are a goal of COVID-19
vaccines and have received emergency use authorization as therapeutics. However, viral …

Background High-risk patients, often immunocompromised and not responding to vaccine,
continue to experience severe coronavirus disease 2019 (COVID-19) and death …

The mutation rate of the Omicron sublineage has led to baseline resistance against all
previously authorized anti-Spike monoclonal antibodies (mAbs). Nevertheless, in case more …

COVID-19 in immunocompromised hosts has emerged as a difficult therapeutic
management problem. Immunocompromised hosts mount weak responses to SARS-CoV-2 …

Although neutralizing antibodies against the SARS-CoV-2 spike (S) protein are a goal of
most COVID-19 vaccines and being developed as therapeutics, escape mutations could …

SARS-CoV-2 mutations that cause resistance to monoclonal antibody (mAb) therapy have
been reported. However, it remains unclear whether in vivo emergence of SARS-CoV-2 …

Monoclonal antibodies (mAbs) directed against the spike of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) are effective therapeutic options to combat …

SARS-CoV-2 causes severe acute respiratory syndrome, which has led to significant
morbidity and mortality around the world. Since its emergence, extensive prophylactic and …

SARS-CoV-2 variants that escape neutralization and potentially affect vaccine efficacy have
emerged. T cell responses play a role in protection from reinfection and severe disease, but …